- Home
- LPTX vs CFBK Comparison
LPTX vs CFBK Comparison
Compare LPTX & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CFBK
- Stock Information
- Founded
- LPTX 2011
- CFBK 1892
- Country
- LPTX United States
- CFBK United States
- Employees
- LPTX N/A
- CFBK N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CFBK Major Banks
- Sector
- LPTX Health Care
- CFBK Finance
- Exchange
- LPTX Nasdaq
- CFBK Nasdaq
- Market Cap
- LPTX 119.6M
- CFBK 141.5M
- IPO Year
- LPTX N/A
- CFBK 1998
- Fundamental
- Price
- LPTX $0.34
- CFBK $21.81
- Analyst Decision
- LPTX Buy
- CFBK
- Analyst Count
- LPTX 2
- CFBK 0
- Target Price
- LPTX $8.00
- CFBK N/A
- AVG Volume (30 Days)
- LPTX 5.9M
- CFBK 12.3K
- Earning Date
- LPTX 03-26-2025
- CFBK 05-06-2025
- Dividend Yield
- LPTX N/A
- CFBK 1.29%
- EPS Growth
- LPTX N/A
- CFBK N/A
- EPS
- LPTX N/A
- CFBK 2.06
- Revenue
- LPTX N/A
- CFBK $45,082,000.00
- Revenue This Year
- LPTX N/A
- CFBK N/A
- Revenue Next Year
- LPTX N/A
- CFBK N/A
- P/E Ratio
- LPTX N/A
- CFBK $10.63
- Revenue Growth
- LPTX N/A
- CFBK N/A
- 52 Week Low
- LPTX $0.28
- CFBK $16.92
- 52 Week High
- LPTX $4.79
- CFBK $31.17
- Technical
- Relative Strength Index (RSI)
- LPTX 33.17
- CFBK 36.38
- Support Level
- LPTX $0.28
- CFBK $21.82
- Resistance Level
- LPTX $0.65
- CFBK $22.30
- Average True Range (ATR)
- LPTX 0.05
- CFBK 0.42
- MACD
- LPTX 0.02
- CFBK 0.05
- Stochastic Oscillator
- LPTX 16.22
- CFBK 31.63
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.